CD8A and cancer: Blockade of LAIR-1 has also been shown to increase the number of tumor-infiltrating CD4+ and CD8+ T cells and enhance the efficacy of anti-PD-L1 treatment in humanized murine xenograft models of several cancers, including colon- and pancreatic cancer (176, 177).